Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Vera Therapeutics Inc

Healthcare US VERA

33.235USD
1.97(6.28%)

Last update at 2026-06-04T17:56:00Z

Day Range

31.2333.28
LowHigh

52 Week Range

7.7350.78
LowHigh

Fundamentals

  • Previous Close 31.27
  • Market Cap2031.06M
  • Volume489102
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-90.72700M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -89.05500M -32.60800M -53.41200M -11.85300M
Minority interest - - - -
Net income -89.05600M -32.60900M -53.41300M -11.85400M
Selling general administrative 21.91M 11.92M 4.04M 4.41M
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation -0.84600M 0.18M 0.25M 0.51M
Ebit -90.05700M -34.57800M -52.24100M -11.96100M
Ebitda -90.90300M -34.40200M -49.99900M -11.03200M
Depreciation and amortization -0.84600M 0.18M 2.24M 0.93M
Non operating income net other -2.84000M 1.81M - -
Operating income -90.90300M -34.40200M -52.24100M -11.96100M
Other operating expenses 90.90M 34.40M 49.24M 11.70M
Interest expense 0.99M 0.02M 0.17M 0.05M
Tax provision 0.00100M 0.00100M 0.00100M 0.00100M
Interest income 1.75M 0.01M 0.00800M 0.16M
Net interest income 0.76M -0.00500M -0.09500M 0.11M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.00100M 0.00100M 0.00100M 0.00100M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 90.90M 34.40M 49.24M 11.70M
Cost of revenue - - - -
Total other income expense net 1.85M 1.79M -1.17100M 0.11M
Discontinued operations - - - -
Net income from continuing ops 89.06M -32.60900M -53.41300M -11.85400M
Net income applicable to common shares 89.06M -32.60900M -53.41300M -11.85400M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 175.55M 131.44M 83.75M 54.55M 5.38M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 4.83M 11.04M 2.86M 0.08M 0.00400M
Total liab 73.86M 54.53M 14.16M 143.90M 41.93M
Total stockholder equity 101.69M 76.91M 69.59M -89.34800M -36.54800M
Deferred long term liab - - - - -
Other current liab 8.75M 10.96M 6.30M 0.96M 0.22M
Common stock 0.04M 0.03M 0.02M 0.00400M 0.00400M
Capital stock 0.04M 0.03M 0.02M 0.00000M 0.00000M
Retained earnings -309.10200M -213.11200M -124.05600M -91.44700M -38.03400M
Other liab - 0.29M 1.54M 1.92M 0.76M
Good will - - - - -
Other assets 0.00000M 0.46M 0.34M 0.29M 0.42M
Cash 45.68M 114.65M 79.67M 53.65M 3.19M
Cash and equivalents - - - - -
Total current liabilities 22.30M 25.60M 7.69M 2.41M 1.06M
Current deferred revenue - - - 0.53M 0.38M
Net debt 8.03M -83.36700M -74.75100M -53.65200M -3.06300M
Short term debt 2.44M 2.65M - 0.00200M 0.12M
Short long term debt - - - - -
Short long term debt total 53.71M 31.29M 4.92M 0.00200M 0.13M
Other stockholder equity 410.49M 290.22M 193.63M 2.10M 1.49M
Property plant equipment - 0.05M - - 1.39M
Total current assets 165.54M 125.70M 82.54M 54.26M 3.56M
Long term investments - 0.06M 0.87M - -
Net tangible assets - 76.91M 69.59M -89.34800M -36.54800M
Short term investments 115.03M 71.19M 0.87M - -
Net receivables - - - 0.05M -
Long term debt 49.88M 24.81M 4.92M - -
Inventory - - - 0.47M -
Accounts payable 11.12M 11.99M 1.39M 0.91M 0.34M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.25M -0.22400M -83.74800M - -1.02000M
Additional paid in capital - - - - -
Common stock total equity - 0.03M 0.02M - -
Preferred stock total equity - - - - -
Retained earnings total equity - -213.11200M -124.05600M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 6.95M 0.51M 0.34M 0.29M 0.42M
Deferred long term asset charges - - - - -
Non current assets total 10.00M 5.74M 1.21M 0.29M 1.82M
Capital lease obligations 3.83M 6.48M - 0.00200M 0.13M
Long term debt total - 24.81M 4.92M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -70.49000M -4.20400M -0.04200M -0.12500M
Change to liabilities 17.64M 5.87M 0.57M -0.29100M
Total cashflows from investing activities -70.55200M -4.20400M -0.04200M -0.12500M
Net borrowings 19.82M 4.92M 5.47M -0.18800M
Total cash from financing activities 101.93M 53.88M 85.29M -0.13700M
Change to operating activities -3.85900M 3.04M -0.44400M 0.81M
Net income -89.05600M -32.60900M -53.41300M -11.85400M
Change in cash -36.21500M 25.97M 50.44M -10.55100M
Begin period cash flow 79.97M 54.00M 3.56M 14.11M
End period cash flow 43.75M 79.97M 54.00M 3.56M
Total cash from operating activities -67.59600M -23.70800M -34.80900M -10.28900M
Issuance of capital stock 86.13M 51.18M 80.00M 0.00000M
Depreciation -0.84600M 0.18M 0.25M 0.51M
Other cashflows from investing activities - -4.20400M - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock 2.08M 48.96M - -
Other cashflows from financing activities 15.80M 2.71M 85.42M 0.05M
Change to netincome 8.89M -0.67800M 18.21M 0.54M
Capital expenditures 0.06M 0.00000M 0.10M 0.12M
Change receivables - - - -
Cash flows other operating -4.22300M 3.54M - -
Exchange rate changes - - - -
Cash and cash equivalents changes -36.21500M 25.97M - -
Change in working capital 6.75M 3.51M 0.12M 0.52M
Stock based compensation 8.89M 3.01M 0.33M 0.26M
Other non cash items 6.67M 4.00M 16.71M 0.17M
Free cash flow -67.65800M -23.70800M -34.90800M -10.41400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
VERA
Vera Therapeutics Inc		 1.97 6.28% 33.23 - - - 25.69 -27.1689
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Vera Therapeutics Inc

8000 Marina Boulevard, Brisbane, CA, United States, 94005

Key Executives

Name Title Year Born
Dr. Marshall Fordyce M.D. Founder, Pres, CEO & Director 1974
Mr. Sean P. Grant M.B.A. Chief Financial Officer 1985
Dr. Celia Lin M.D. Chief Medical Officer 1975
Mr. Joseph R. Young M.B.A. Sr. VP of Fin. & Chief Accounting Officer 1973
Mr. Julien E. Capers J.D. VP & Head of Legal NA
Ms. Kelly Rauber VP & Head of HR NA
Mr. Tom Doan Sr. VP of Devel. Operations 1972
Ms. Lauren Frenz Chief Bus. Officer 1985
Dr. Joanne Curley Ph.D. Chief Devel. Officer 1969
Dr. Marshall W. Fordyce M.D. Founder, President, CEO & Director 1975

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions